Answers are grounded in this paper and cite their sources.
Although anti-thymocyte globulin with cyclosporine (rATG/CsA), bone marrow transplantation, and eltrombopag are the cornerstone treatment for severe and very severe aplastic anemia (SAA/vSAA), oxymetholone remains beneficial in ineligible patients.This study was conducted to compare the realistic effectiveness of oxymetholone with rATG/CsA in SAA/vSAA.The primary outcome was 2-year overall response rate (ORR).Factors associated with ORR were evaluated using a logistic model.The secondary outcomes were 3-, 6-, 12-and 18-month ORR and overall survival (OS).Kaplan-Meier estimates were calculated for OS and risk factors related to PFS were assessed using Cox proportional hazards models.A total of 47 eligible patients and 53 treatment periods were included.The ORR of rATG/CsA treatment was significantly higher than for oxymetholone (46.7 vs. 15.8%,p=0.025).With a median follow-up time of 20.4 months, OS among patients initially treated with rATG/CsA and oxymetholone were 78.6% and 28. 5% , respectively ( p= 0. 001) .However, patients responding to oxymetholone had a longer median survival compared with patients having no response to rATG/CsA as front-line treatment (11.8 years and 2. 9 years, respectively) although a statistically significant difference between the two groups was undetected (p=0.092).Severity of disease and response to treatment were significant predictors of mortality from AA.This study revealed the superiority of rATG/ CsA in response and survival improvement.However, the patient' s situation, needing to start oxymetholone as front-line treatment, oxymetholone, still had improved survival among the responders.Patients unresponsive to oxymetholone within 3 months should be switched throughout the treatment.
No takes yet. Share an insight, caveat, or question.
Penthinapong et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: